anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants age ≥ 4 weeks old weighing 14 to \< 25 kg will receive cobicistat tablet for oral suspension (TOS) 90 mg, once daily and F/TAF TOS 120/15 mg, once daily with either ATV or DRV or lopinavir boosted by ritonavir (LPV/r). Minimum age and weight for ATV is ≥ 3 months and ≥ 5 kg, minimum age and weight for DRV is ≥ 3 years and ≥ 15 kg; participants receiving LPV/r will not receive cobicistat TOS.
Most of the drugs used to treat cancer are metabolized by hepatic enzymes such as cytochrome P450 or Glutathion-S-Transferase (GST). These enzymatic pathways can be more or less active in the drug's metabolism according to the given polymorphism of each patient (pharmacogenomics).

The current hypothesis is that some functional polymorphisms of genes, which control important enzymes in Busulfan metabolism, contribute to the observed interindividual variability in PK of this drug. This variability can hence predict the resistance as well as the toxicity from a drug in patients who have cancer. The pharmacokinetic profile of different drugs, which have a hepatic metabolism, can be dramatically modified by these polymorphisms. Busulfan is a major drug used in the conditioning regimen before hematopoietic stem cell transplantation, particularly in children in whom total body irradiation has to be avoided. This drug has a narrow therapeutic index. At a lower systemic exposure than the targeted one, Busulfan has insufficient activity and hence an increased risk of transplant rejection and leukemic relapse.

At higher systemic exposures, the toxicity risk increases dramatically with an elevated incidence of hepatic veno-occlusive disease (VOD). Pharmacokinetic monitoring of Busulfan allows optimal dosing. The recommended doses are based on the weight, body surface area or age. Nevertheless, a majority of patients will still need an adjustment of the dose administered after their first dose: this will result in a cumulative systemic exposure that will be over or under therapeutic. Busulfan is metabolized principally by the GSTA1, as well as by other GST enzymes like the GSTM1 and GSTP1. These enzymes are present in the liver as well as in the intestinal cells and are up regulated in the digestive system of young children.With this study we will look for the polymorphism in GST genes, look at the Busulfan IV pharmacokinetics and finally look at the GST alpha enzyme activity and see if there is a correlation with clinical end points. This study will also study any correlation with other genes (repair DNA genes, CYP etc..) that could be correlated with Busulfan and/or cyclophosphamide. This study will also allow to do some DNA banking for future studies in genetics. This multicentric study is sponsor by the Swiss pediatric Oncology Group and is a European Bone and Marrow Transplantation study open in 6 countries (Switzerland, Canada, Italy, Holland, Tscèque republic, ). Pilot study are first analyze with St. Justine Hospital then with the other center at a later stage.
Cerebral palsy is a motor disorder caused by the damage to the developing brain. Feeding and swallowing difficulties are common in children with cerebral palsy (CP). Poor postural control and oral motor dysfunction results in extended feeding time, frequent coughing, choking and excessive drooling affecting their health and quality of life. The brain damage in CP is permanent that cannot be fixed however different oral motor exercises, oral facial facilitation and oral sensorimotor interventions are widely used for drool reduction and feeding difficulties in children with CP. Spastic cerebral palsy is one of most prevalent type of CP that is characterized by increased tone and stiffness of muscles. This research will be conducted to evaluate the comparative effects of oral motor facilitation technique (OMFT) and traditional oral motor exercises on drooling and feeding skills of children with spastic CP. OMFT is a complete protocol with a combination of techniques to deal with oral motor difficulties This study will be a randomized control trial. A total number of 12 children with Spastic cerebral palsy ( GMFS III-V) both male/female, between age range 3-12 and with feeding difficulties will be included in the study. Children with cerebral palsy and other co morbidities, seizures, risk of aspiration and who are on tube feeding will be excluded. Participants will be randomly allocated to two groups, either Group A (receiving OMFT) or Group B (receiving traditional oral motor exercise). Baseline scores will be recorded by using standardized tools OMAS for oral motor skill during feeding and DIS for drool severity with the consent of authors. Therapeutic sessions will be scheduled 3 days per week and 30 min a day for each group. The effects of interventions on drooling and feeding skills will be assessed after 8 and 16 weeks of sessions. Recorded data of all variables will be analyzed by using statistical package for social sciences (SPSS) for Windows Software, version 21.
Six 21-day cycles of docetaxel plus weekly bavituximab. Patients who have not experienced disease progression will continue to receive bavituximab weekly until progression.
Each participant will be entered into a lottery daily, but participants will only be eligible to collect their winnings if they walked at least 7000 steps the day before. Participants will receive either an email or text message (based on the participant's preference) stating whether or not they won the lottery and if they met their target step goal. If both occur, the participant will be told how much money he or she won. Non-adherent participants will receive messages about how much they would have won had they met the target step goal.
FIELD: medicine. ^ SUBSTANCE: invention concerns the solid medicinal composition, including flupirtin or its physiologically comprehensible salts as biologically active substance. At least, one part of flupirtin exists as preparative ready form with the slowed down liberation of the active component. The preparative ready form contains the pressed forms flupirtin, which are preferably in regular intervals covered by a prolonging component. Form pressing of flupirtin is characterised by the size of particles of 160-800 mcm, in bulk volume less than 5 ml/g and preferably are spherical or close to spherical. The prolonging component provides diffused-controllable flupirtin release and preferably includes polymer or a copolymer from acrylic acid, derivatives of acrylic acid, methyl-acrylic acid and-or derivatives of the methyl-acrylic acid, or their admixtures. ^ EFFECT: new flupirtin composition provides uniform and long release of active substance during long time, frequency of reception to two times day, more rare implication of side effects and a risk exception of a "dose dumping". ^ 16 cl, 3 dwg, 3 ex
Before starting the study (pre-test/0. week), "Patient Information Form", "OAG" and "OHQoL-UK" were administered to all group participants to evaluate the level of oral mucositis in patients. In addition to routine oral mucositis treatment, patients with DM in the black mulberry syrup group gargled with 1 tablespoon (10 cc) of pure black mulberry syrup for 1 minute 15-20 minutes before meals 3 times a day for 14 days. "OAG" and "OHQoL-UK" were administered again on the 7th day (interim-measurement) and 14th day/end of the study (post-test).
PCT No. PCT/SE95/00875 Sec. 371 Date Dec. 31, 1996 Sec. 102(e) Date Dec. 31, 1996 PCT Filed Jul. 18, 1995 PCT Pub. No. WO96/02260 PCT Pub. Date Feb. 1, 1996The invention relates to a method for promoting the healing of dermal wounds by applying a composition containing chitosan and the polysaccharide, heparin or heparan sulfate. Heparin or heparan sulfate can be immobilized to chitosan by ionic or covalent bonds, and the degree of N-acetylation of chitosan can range from 25% to 90%. The composition can include a cellulose derivative as an additional polysaccharide to increase the viscosity of the composition. The combination of chitosan and polysaccharide, when applied to a wound site, effectively stimulates and accelerates wound healing.
Febuxostat is an XO inhibitor. Based on a drug interaction study in healthy patients, febuxostat altered the metabolism of theophylline (a substrate of XO) in humans [see Clinical Pharmacology (12.3)]. Therefore, use with caution when coadministering febuxostat with theophylline.

  


A drug interaction study of febuxostat and azathioprine, also metabolized by XO, showed an increase in exposure of 6-mercaptopurine which may lead to toxicity [see Clinical Pharmacology (12.3)]. Drug interaction studies of febuxostat with other drugs that are metabolized by XO (e.g., mercaptopurine) have not been conducted. Febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see Contraindications (4)].
NEW MATERIAL:A compound expressed by formula I (R1 and R2 are H or 1-3C alkyl; X is OH<-> or halogen anion). EXAMPLE:Technetium-99m-pentane-2,4-dione-bis(N-methylthiosemicarbazone) complex. USE:A diagnostic in vivo radioactive medicine, cerebral, myocardial and pancreatic imaging agent. PREPARATION:For example, a pentane-2,4-dithione-bis(N-alkylthiosemicarbazone) expressed by formula II is dissolved in a phosphoric acid buffer solution (pH8.0) free of dissolved oxygen and a solution of stannous chloride solution in hydrochloric acid and a solution of sodium perthechnetate (99mTc) are added thereto. Nitrogen gas is then bubbled to carry out reaction while heating at 85 deg.C. The reaction mixture is subsequently extracted with hexane, which is thin distilled away to afford the aimed complex expressed by formula I.
Patients using VANIQA should receive the following information and instructions:

  1. This medication is not a depilatory, but rather appears to retard hair growth to improve the condition and the patient's appearance. Patients will likely need to continue using a hair removal method (e.g., shaving, plucking, etc.) in conjunction with VANIQA (eflornithine hydrochloride) Cream, 13.9%.

  2. Onset of improvement was seen after as little as 4-8 weeks of treatment in the 24-week clinical trials. The condition may return to pretreatment levels 8 weeks after discontinuing treatment. 

  3. If skin irritation or intolerance develops, direct the patient to temporarily reduce the frequency of application (e.g., once a day). If irritation continues, the patient should discontinue use of the product.




Refer to the Patient Information Leaflet for additional important information and instructions.
If subjects are eligible for the study, they will be randomized into one of four different exercise training groups. Before training (and twice after 3 months of training) subjects will participate in a "clinical study" in which they will be required to stay overnight in the hospital. During the clinical study, the research team will perform a series of metabolic tests. Before and after the 3 months of training, the research team will assess subjects "free-living" 24h blood sugar control using a Continuous Glucose Monitor (CGM). The research team will measure several other relevant clinical markers (e.g., whole body and regional body fat assessments \[Dual Energy X-ray Absorptiometry (DEXA) and Magnetic Resonance Imager (MRI)\], hepatic lipid accumulation \[MRI analysis\], blood lipid profile, resting metabolic rate, glycated hemoglobin \[hemoglobin A1c\]). After the first 3 months of training, adherence to the subjects assigned training program will be tracked for the next 9 months (1 year of training in total). One year after initiating a training program, subjects will be asked to return to the clinic for a quick follow-up visit where the research team will complete some standard clinical assessments (e.g., body weight, body composition, blood pressure, and a blood sample).
PURPOSE:To obtain the titled preparation containing granulocyte colony stimulating factor and at least one surface active agent. CONSTITUTION:A stable granulocyte colony stimulating factor (G-CSF)- containing preparation comprising 1pts.wt. G-SCF [e.g. human G-CSF having 19,000+ or -1,000 (by sodium dodecyl sulfate-polyacryl-amide gel electrophoresis), at least one isoelectric point of pI=5.5+ or -0.1, pI=5.8+ or -0.1 and pI=6.1+ or -1 and an amine acid sequence from N end to 21st having a group shown by the formula] and 1-10,000pts.wt. at least one surface active agent (e.g. sorbitan fatty acid ester of glycerin fatty acid ester of nonionic surface active agent, lecithin of natural occurring type surface active agent). The preparation can be used by various administration forms such as oral administration and parenteral administration such as many injections, etc. Adsorption on the wall of container can be prevented and consumption of expensive component can be hindered.
At least 10 healthy participants aged from 18 to 60 years old with symmetric walking at visual analysis. Participants will be excluded if pregnant, if they present with pharmacologic therapies which could affect balance and walking, and if they suffered from (or presently present with) orthopedic or neurologic conditions potentially impairing walking.
Two 1 hour assessments. At each assessment, participant will complete a survey, supply a saliva sample, do a toothpick test, and take a plaque photo.
BACKGROUND: Patient navigation increases linkage to hepatitis C virus (HCV) care following release from prison; however, little is known about the services patient navigators should provide to maximize linkage to care. We aimed to identify perceived barriers and facilitators to linkage to HCV care post-release, and to determine patient navigator services and characteristics best suited to address barriers to linkage to care among people released from prison.
METHODS: Ten semi-structured interviews were conducted with adult (age ≥18 years) men living with chronic HCV, released from the largest Quebec provincial prison, and linked to HCV care by a patient navigator. Interviews were guided by the Socio-Ecological Model (SEM) and aimed to explore the multi-level barriers and facilitators to linkage to HCV care post-release. Interviews were audio-recorded, transcribed, and analyzed using a deductive, thematic approach.
RESULTS: The median age of participants was 54 years. Barriers to linkage to HCV care included competing priorities post-release (e.g., substance use, mental health issues, unstable housing), stigma (related to HCV, injection drug use, and incarceration), and lack of transportation. Facilitators included social support, established relationships with existing healthcare providers, prior cure with direct-acting antivirals, and HCV-related health literacy and knowledge. Perceived essential patient navigator services to enhance linkage included pre-release discharge appointments, housing assistance, and facilitated transportation to HCV appointments. Ensuring a consistent, non-judgemental, and empathetic patient navigator were considered important characteristics; lived experiences of incarceration and/or HCV were not felt to be essential for a patient navigator.
CONCLUSIONS: Interventions that seek to improve linkage to HCV care for people following release from prison should address many levels (individual, interpersonal, and policy) of the SEM. While people experience several competing priorities post-release, having an empathetic and consistent patient navigator, regardless of their lived experiences of HCV and/or incarceration, may improve linkage to HCV care post-release.
Background: Thrombosed external haemorrhoids are one of the most frequent anorectal emergencies. They are associated with swelling and intense pain. Internal sphincter hypertonicity plays a role in the aetiology of the pain. This study evaluated the efficacy and safety of an intersphincteric injection of botulinum toxin for pain relief in patients with thrombosed external haemorrhoids. Methods: Thirty patients with thrombosed external haemorrhoids who refused surgical operation were randomized into two groups. Patients received an intrasphincteric injection of either 0·6 ml saline or 0·6 ml of a solution containing 30 units botulinum toxin. Anorectal manometry was performed before treatment and 5 days afterwards.Results: After 5 days of treatment, the maximum resting pressure fell in both groups, but was significantly lower in the botulinum toxin group (P = 0·004). Pain intensity was significantly reduced within 24 h of botulinum toxin treatment (P \< 0·001), but only after 1 week in the placebo group (P = 0·019). Conclusion: A single injection of botulinum toxin into the anal sphincter seems to be effective in rapidly controlling the pain associated with thrombosed external haemorrhoids, and could represent an effective conservative treatment for this •condition.
Repotrectinib is a kinase inhibitor. The molecular formula for repotrectinib is C18H18FN5O2 and the molecular weight is 355.37 Daltons. The chemical name is (3R,11S)-6-Fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentaazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4,6,8,15(22),16,19-heptaen-14-one. The chemical structure of repotrectinib is as follows:

Repotrectinib is a white to off-white powder. 

AUGTYRO (repotrectinib) capsules for oral use are supplied as printed hard shell capsules containing 40 mg of repotrectinib. Inactive ingredients are microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium, and colloidal silicon dioxide.

The white opaque capsule shell contains gelatin and titanium dioxide. The printing ink contains shellac and FD & C blue #2 aluminum lake.

AUGTYRO (repotrectinib) capsules for oral use are supplied as printed hard shell capsules containing 160 mg of repotrectinib. Inactive ingredients are microcrystalline cellulose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, and colloidal silicon dioxide.

The blue opaque capsule shell contains gelatin, titanium dioxide and FD & C blue #1. The printing ink contains shellac and titanium dioxide.
PURPOSE:The titled pharmaceutical, prepared by incorporating doxycycline hydrochloride with a specific amount of bromelain or callicrein, and having increased antimicrobial activity. CONSTITUTION:A doxycycline hydrochloride pharmaceutical, prepared by incorporating one mug potency of doxycycline hydrochloride with 0.1-100, more preferably 0.5-10, bromelain units bromelain or 0.1-100, preferably 0.1-1, biological units callicrein, and further mixing with an adjuvant, e.g. an excipient, sweetening agent, colorant or binding agent, etc. or granulating the resultant mixture, and having improved antimicrobial activity. The dosage form may be a tablet, pill, sugar-coated tablet, capsule, suppository, granule or multilayered pharmaceutical, etc. EFFECT:The enhanced antimicrobial activity provides the reduction in the dose per time, and the side effects can be reduced.
Osteoarthritis and rheumatoid arthritis are common chronic diseases, which have high morbidity and hard to heal, therefore a long period medicine treatment is required. Life of the patient can be threatened if the long period medicine treatment is not well insisted. Currently, among medicine for arthritis, nonsteroidal anti-inflammatory drugs are most important. But currently oral preparation account for the most portions, which has more side effects. Etodolac belongs to the indole nonsteroidal anti-inflammatory drugs, which play an important role in arthritis treatment. But the current oral preparation has a plurality of side effects, which brings trouble to the long period treatment in patients. Therefore the present invention develops an external preparation of Etodolac, which not only greatly reduces side effects of the drugs, but also applicable for long period treatment of arthritis particularly.
Barium sulfate volume and method of administration are determined by individual technique, and may vary with differing patient and procedure characteristics. Add 67 mL of water to create a 135mL suspension with a density of 225% w/v (81% w/w). After adding water, invert bottle, tap bottom to loosen barium, and shake vigorously for 30 seconds. Let stand at least 5 minutes. Add additional water as necessary to achieve the desired % mixture. Replace lid, and again shake vigorously for 30 seconds.
A hair growth stimulant is provided. The hair growth stimulant uses carbonized chestnut burrs that exhibit excellent stimulatory effects on hair restoration and hair growth effects without causing side effect and toxicity. The hair growth stimulant exhibits excellent stimulatory effects on hair restoration without causing any side effect and toxicity in humans and stimulates hair roots to greatly contribute to hair growth. Therefore, the hair growth stimulant is effective in preventing hair loss and grayness. In addition, the hair growth stimulant is formulated into a cream or ointment preparation, which is highly effective in promoting the restoration of hair, to considerably shorten the time required for the treatment of hair loss. Furthermore, the hair growth stimulant uses vegetable ingredients only, thus causing no side effect in humans. Moreover, the hair growth stimulant is softly applicable to the scalp, thus offering convenience in use.
Participants receive SBRT once every 3 days for 3, 4, 5, or 8 fractions (dependent on tumor type/location; 45-70 Gray \[Gy\] total) over approximately 2 weeks PLUS pembrolizumab 200 mg via intravenous (IV) infusion once every 3 weeks for up to 17 cycles (up to approximately 1 year). Each cycle is 21 days.
It is well established that neutrophils adopt malleable polymorphonuclear shapes to migrate through narrow interstitial tissue spaces1-3. However, how polymorphonuclear structures are assembled remains unknown4. Here we show that in neutrophil progenitors, halting loop extrusion-a motor-powered process that generates DNA loops by pulling in chromatin5-leads to the assembly of polymorphonuclear genomes. Specifically, we found that in mononuclear neutrophil progenitors, acute depletion of the loop-extrusion loading factor nipped-B-like protein (NIPBL) induced the assembly of horseshoe, banded, ringed and hypersegmented nuclear structures and led to a reduction in nuclear volume, mirroring what is observed during the differentiation of neutrophils. Depletion of NIPBL also induced cell-cycle arrest, activated a neutrophil-specific gene program and conditioned a loss of interactions across topologically associating domains to generate a chromatin architecture that resembled that of differentiated neutrophils. Removing NIPBL resulted in enrichment for mega-loops and interchromosomal hubs that contain genes associated with neutrophil-specific enhancer repertoires and an inflammatory gene program. On the basis of these observations, we propose that in neutrophil progenitors, loop-extrusion programs produce lineage-specific chromatin architectures that permit the packing of chromosomes into geometrically confined lobular structures. Our data also provide a blueprint for the assembly of polymorphonuclear structures, and point to the possibility of engineering de novo nuclear shapes to facilitate the migration of effector cells in densely populated tumorigenic environments.
The nutrition equal attention control intervention is a single-session, 60- minute Information-Motivation-Behavioral (IMB) skills-based intervention addressing healthy eating. The healthy eating intervention uses a one-on-one guided conversation between the interventionist and the participant. The intervention addresses (1) information about current eating patterns and recommendations for healthy alternatives (20 minutes), (2) motivations for improving healthy eating by providing feedback to participants on personal responsibility, a menu of alternative change options, a decision balance exercise, and eating goal setting (10 minutes), and (3) Behavioral Self-Management Component (30 minutes) that covers eating scenarios, participant responses, and healthy alternatives to the scenario and the participants feedback.
Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.